Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations

Susan Price, Pamela A. Shaw, Amy Seitz, Gyan Joshi, Joie Davis, Julie E. Niemela, Katie Perkins, Ronald L. Hornung, Les Folio, Philip S. Rosenberg, Jennifer M. Puck, Amy P. Hsu, Bernice Lo, Stefania Pittaluga, Elaine S. Jaffe, Thomas A. Fleisher, V. Koneti Rao, Michael J. Lenardo

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) presents in childhood with nonmalignant lymphadenopathy and splenomegaly associated with a characteristic expansion of mature CD4 and CD8 negative or double negative T-cell receptor αβ+ T lymphocytes. Patients often present with chronic multilineage cytopenias due to autoimmune peripheral destruction and/or splenic sequestration of blood cells and have an increased risk of B-cell lymphoma. Deleterious heterozygous mutations in the FAS gene are the most common cause of this condition, which is termed ALPS-FAS. We report the natural history and pathophysiology of 150 ALPS-FAS patients and 63 healthy mutation-positive relatives evaluated in our institution over the last 2 decades. Our principal findings are that FAS mutations have a clinical penetrance of <60%, elevated serum vitamin B12 is a reliable and accurate biomarker of ALPS-FAS, and the major causes of morbidity and mortality in these patients are the overwhelming postsplenectomy sepsis and development of lymphoma. With longer follow-up, we observed a significantly greater relative risk of lymphoma than previously reported. Avoiding splenectomy while controlling hypersplenism by using corticosteroid-sparing treatments improves the outcome in ALPS-FAS patients. This trial was registered at www.clinicaltrials.gov as #NCT00001350.

Original languageEnglish
Pages (from-to)1989-1999
Number of pages11
JournalBlood
Volume123
Issue number13
DOIs
Publication statusPublished - 27 Mar 2014
Externally publishedYes

Fingerprint

Autoimmune Lymphoproliferative Syndrome
Genes
Cells
Mutation
T-cells
Biomarkers
Vitamin B 12
T-Cell Antigen Receptor
Adrenal Cortex Hormones
Blood
Lymphoma
Hypersplenism
Penetrance
Splenomegaly
B-Cell Lymphoma
Splenectomy
Natural History
Blood Cells
Sepsis
Morbidity

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Price, S., Shaw, P. A., Seitz, A., Joshi, G., Davis, J., Niemela, J. E., ... Lenardo, M. J. (2014). Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood, 123(13), 1989-1999. https://doi.org/10.1182/blood-2013-10-535393

Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. / Price, Susan; Shaw, Pamela A.; Seitz, Amy; Joshi, Gyan; Davis, Joie; Niemela, Julie E.; Perkins, Katie; Hornung, Ronald L.; Folio, Les; Rosenberg, Philip S.; Puck, Jennifer M.; Hsu, Amy P.; Lo, Bernice; Pittaluga, Stefania; Jaffe, Elaine S.; Fleisher, Thomas A.; Rao, V. Koneti; Lenardo, Michael J.

In: Blood, Vol. 123, No. 13, 27.03.2014, p. 1989-1999.

Research output: Contribution to journalArticle

Price, S, Shaw, PA, Seitz, A, Joshi, G, Davis, J, Niemela, JE, Perkins, K, Hornung, RL, Folio, L, Rosenberg, PS, Puck, JM, Hsu, AP, Lo, B, Pittaluga, S, Jaffe, ES, Fleisher, TA, Rao, VK & Lenardo, MJ 2014, 'Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations', Blood, vol. 123, no. 13, pp. 1989-1999. https://doi.org/10.1182/blood-2013-10-535393
Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014 Mar 27;123(13):1989-1999. https://doi.org/10.1182/blood-2013-10-535393
Price, Susan ; Shaw, Pamela A. ; Seitz, Amy ; Joshi, Gyan ; Davis, Joie ; Niemela, Julie E. ; Perkins, Katie ; Hornung, Ronald L. ; Folio, Les ; Rosenberg, Philip S. ; Puck, Jennifer M. ; Hsu, Amy P. ; Lo, Bernice ; Pittaluga, Stefania ; Jaffe, Elaine S. ; Fleisher, Thomas A. ; Rao, V. Koneti ; Lenardo, Michael J. / Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. In: Blood. 2014 ; Vol. 123, No. 13. pp. 1989-1999.
@article{a2c12d544c6946d29f1d4f8ed4459e21,
title = "Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations",
abstract = "Autoimmune lymphoproliferative syndrome (ALPS) presents in childhood with nonmalignant lymphadenopathy and splenomegaly associated with a characteristic expansion of mature CD4 and CD8 negative or double negative T-cell receptor αβ+ T lymphocytes. Patients often present with chronic multilineage cytopenias due to autoimmune peripheral destruction and/or splenic sequestration of blood cells and have an increased risk of B-cell lymphoma. Deleterious heterozygous mutations in the FAS gene are the most common cause of this condition, which is termed ALPS-FAS. We report the natural history and pathophysiology of 150 ALPS-FAS patients and 63 healthy mutation-positive relatives evaluated in our institution over the last 2 decades. Our principal findings are that FAS mutations have a clinical penetrance of <60{\%}, elevated serum vitamin B12 is a reliable and accurate biomarker of ALPS-FAS, and the major causes of morbidity and mortality in these patients are the overwhelming postsplenectomy sepsis and development of lymphoma. With longer follow-up, we observed a significantly greater relative risk of lymphoma than previously reported. Avoiding splenectomy while controlling hypersplenism by using corticosteroid-sparing treatments improves the outcome in ALPS-FAS patients. This trial was registered at www.clinicaltrials.gov as #NCT00001350.",
author = "Susan Price and Shaw, {Pamela A.} and Amy Seitz and Gyan Joshi and Joie Davis and Niemela, {Julie E.} and Katie Perkins and Hornung, {Ronald L.} and Les Folio and Rosenberg, {Philip S.} and Puck, {Jennifer M.} and Hsu, {Amy P.} and Bernice Lo and Stefania Pittaluga and Jaffe, {Elaine S.} and Fleisher, {Thomas A.} and Rao, {V. Koneti} and Lenardo, {Michael J.}",
year = "2014",
month = "3",
day = "27",
doi = "10.1182/blood-2013-10-535393",
language = "English",
volume = "123",
pages = "1989--1999",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations

AU - Price, Susan

AU - Shaw, Pamela A.

AU - Seitz, Amy

AU - Joshi, Gyan

AU - Davis, Joie

AU - Niemela, Julie E.

AU - Perkins, Katie

AU - Hornung, Ronald L.

AU - Folio, Les

AU - Rosenberg, Philip S.

AU - Puck, Jennifer M.

AU - Hsu, Amy P.

AU - Lo, Bernice

AU - Pittaluga, Stefania

AU - Jaffe, Elaine S.

AU - Fleisher, Thomas A.

AU - Rao, V. Koneti

AU - Lenardo, Michael J.

PY - 2014/3/27

Y1 - 2014/3/27

N2 - Autoimmune lymphoproliferative syndrome (ALPS) presents in childhood with nonmalignant lymphadenopathy and splenomegaly associated with a characteristic expansion of mature CD4 and CD8 negative or double negative T-cell receptor αβ+ T lymphocytes. Patients often present with chronic multilineage cytopenias due to autoimmune peripheral destruction and/or splenic sequestration of blood cells and have an increased risk of B-cell lymphoma. Deleterious heterozygous mutations in the FAS gene are the most common cause of this condition, which is termed ALPS-FAS. We report the natural history and pathophysiology of 150 ALPS-FAS patients and 63 healthy mutation-positive relatives evaluated in our institution over the last 2 decades. Our principal findings are that FAS mutations have a clinical penetrance of <60%, elevated serum vitamin B12 is a reliable and accurate biomarker of ALPS-FAS, and the major causes of morbidity and mortality in these patients are the overwhelming postsplenectomy sepsis and development of lymphoma. With longer follow-up, we observed a significantly greater relative risk of lymphoma than previously reported. Avoiding splenectomy while controlling hypersplenism by using corticosteroid-sparing treatments improves the outcome in ALPS-FAS patients. This trial was registered at www.clinicaltrials.gov as #NCT00001350.

AB - Autoimmune lymphoproliferative syndrome (ALPS) presents in childhood with nonmalignant lymphadenopathy and splenomegaly associated with a characteristic expansion of mature CD4 and CD8 negative or double negative T-cell receptor αβ+ T lymphocytes. Patients often present with chronic multilineage cytopenias due to autoimmune peripheral destruction and/or splenic sequestration of blood cells and have an increased risk of B-cell lymphoma. Deleterious heterozygous mutations in the FAS gene are the most common cause of this condition, which is termed ALPS-FAS. We report the natural history and pathophysiology of 150 ALPS-FAS patients and 63 healthy mutation-positive relatives evaluated in our institution over the last 2 decades. Our principal findings are that FAS mutations have a clinical penetrance of <60%, elevated serum vitamin B12 is a reliable and accurate biomarker of ALPS-FAS, and the major causes of morbidity and mortality in these patients are the overwhelming postsplenectomy sepsis and development of lymphoma. With longer follow-up, we observed a significantly greater relative risk of lymphoma than previously reported. Avoiding splenectomy while controlling hypersplenism by using corticosteroid-sparing treatments improves the outcome in ALPS-FAS patients. This trial was registered at www.clinicaltrials.gov as #NCT00001350.

UR - http://www.scopus.com/inward/record.url?scp=84897531867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897531867&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-10-535393

DO - 10.1182/blood-2013-10-535393

M3 - Article

C2 - 24398331

AN - SCOPUS:84897531867

VL - 123

SP - 1989

EP - 1999

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -